mRNA COVID-19 vaccine effectiveness against SARS-CoV-2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021

Influenza Other Respir Viruses. 2022 Jul;16(4):607-612. doi: 10.1111/irv.12970. Epub 2022 Feb 18.

Abstract

Reduced COVID-19 vaccine effectiveness (VE) has been observed with increasing predominance of SARS-CoV-2 Delta (B.1.617.2) variant. Two-dose VE against laboratory-confirmed SARS-CoV-2 infection (symptomatic and asymptomatic) was estimated using Cox proportional hazards models with time-varying vaccination status in a prospective rural community cohort of 1266 participants aged ≥12 years. Between November 3, 2020 and December 7, 2021, VE was 56% for mRNA COVID-19 vaccines overall, 65% for Moderna, and 50% for Pfizer-BioNTech. VE when Delta predominated (June to December 2021) was 54% for mRNA COVID-19 vaccines overall, 59% for Moderna, and 52% for Pfizer-BioNTech.

Keywords: COVID-19; SARS-CoV-2; vaccine effectiveness.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • COVID-19 Vaccines*
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Humans
  • Prospective Studies
  • RNA, Messenger
  • Rural Population
  • SARS-CoV-2 / genetics
  • Vaccine Efficacy
  • Wisconsin / epidemiology

Substances

  • COVID-19 Vaccines
  • RNA, Messenger

Supplementary concepts

  • SARS-CoV-2 variants